December 18, 2024

Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Heinzerling et al explored the efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy...

The ASCO Post

December 17, 2024

FDA Rejects J&J’s Injectable Lung Cancer Drug

FDA declines to approve Johnson & Johnson's Rybrevant injectable for non-small cell lung cancer due to observations during pre-approval inspection unrelated to drug formulation, efficacy, or safety. J&J is working to resolve the issues.

Reuters

December 12, 2024

Melanoma Recurrence Signs with ATLAS Guide

Study published in the Journal of the American Academy of Dermatology explores key symptoms and detection strategies for melanoma recurrence, providing potential improvements for surveillance protocols.

Conexiant

December 09, 2024

Metformin May Impact Immunotherapy in NSCLC

Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Jou...

The ASCO Post

December 09, 2024

4-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC

Neoadjuvant chemotherapy with vs without nivolumab conferred a higher pathologic complete response rate and long-term event-free survival benefit in Asian patients with resectable non–small cell lung ...

The ASCO Post

December 05, 2024

FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

On December 4, 2024, the U.S. Food and Drug Administration approved durvalumab (Imfinzi) for adults with limited-stage small cell lung cancer (SCLC) whose disease has not progressed following concurre...

The ASCO Post

December 05, 2024

FDA Approves Imfinzi for Limited Stage SCLC

In a late-stage trial, the drug showed statistically significant improvement in overall survival compared to a placebo.

Reuters

December 05, 2024

FDA Grants Approval to New Bispecific Antibody for NSCLC and Pancreatic Adenocarcinoma

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to the HER2 × HER3 bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with advanced or metastatic NRG1...

The ASCO Post

December 05, 2024

Bizengri Gets FDA Nod for Cancer

The recommended dose of the therapy is 750 milligrams as an intravenous infusion every 2 weeks.

Reuters